Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Laser activated nanothermolysis of cells

a laser-activated nanothermolysis and cell technology, applied in the field of electromagnetic radiation and nanoparticles medical treatments, can solve the problems of selective and increased thermomechanical damage to the targeted biological body, selective and increased thermomechanical damage to the targeted cancer cell, and not to the normal cells comprising the sampl

Inactive Publication Date: 2012-02-23
LAPOTKO TATIANA MS
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Subsequently, vapor microbubbles are generated from heat produced via absorption of the electromagnetic radiation into the nanoparticulates such that the microbubbles cause selective and increased thermomechanical damage to the targeted biological body.
The electromagnetic radiation is absorbed by the nanoparticulates thereby causing selective and increased thermomechanical effects damaging to the targeted cancer cells, but not to the normal cells comprising the sample.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Laser activated nanothermolysis of cells
  • Laser activated nanothermolysis of cells
  • Laser activated nanothermolysis of cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

In Vitro Laser Activated Nanothermolysis of Tumor Cells Using Nanospheres

[0174]An in vitro model with myeloid K562 cell line, cryopreserved human cells, tumor cells (patient-derived acute B lymphoblast leukemia), both referred to as tumor cells, and normal stem cells are used. Well-defined specific MABs are used as primary MAB for targeting, i.e., CD15 and Glycophorin-A for K562 cells and CD19 for acute B-lymphoblast leukemia cells. Selection of MABs was realized by using flow cytometry. MABs CD 15 and Glycophorin A were selected for K562 cells based on their superior level of expression on surface of those cells. CD 19 was selected in the same way for acute B lymphoblast leukemia (ALL) cells. For controls for the single-cell model, untreated K562 cells are used and for the suspension model, normal stem cells are used.

Specific Targeting Protocol

[0175]Cells at a concentration of 800,000 / ml in phosphate buffer solution (PBS) with 1% fetal bovine serum (FBS) were preincubated with two ...

example 2

[0189]Ex Vivo LANTCET of Human Normal and ALL Leukemia Cells Using Spherical Nanoparticles

[0190]Cryopreserved samples of human bone marrow (BM) taken either from normal donors or patients with the diagnosis of acute B-lymphoblast leukemia (ALL) were used. Suspensions of normal and tumor cells were not mixed. Normal BM samples had no tumor cells and ALL tumor samples consisted mainly of tumor cells where the level of B-lymphoblasts was 94% to 98% in samples from different patients. Three normal and three tumor samples were all obtained from different patients. Normal and tumor samples were prepared and analyzed as separate samples though the same treatment protocol was used for each. Leukemia cells express diagnosis-specific genes that were determined individually for each ALL patient by using standard clinical protocols [53]. Specific MAB, raised against cell membrane receptors corresponding to specific genes, were used for each sample of tumor cells. Phenotyping was performed with ...

example 3

LANTCET of Human Normal and Tumor Cells Using Nanorods or Nanoshells

[0215]Cells and Antibody Conjugates

[0216]K562 cells that have high level of expression of CD33 antigens were used. Primary samples of human bone marrow (BM) taken either from normal donors or patients with the diagnosis of acute myeloid leukemia (AML) were used in experiments. All AML (tumor) samples consisted mainly of tumor cells where the level of B-lymphoblasts was 94 to 98% in samples from different patients. AML cells expressing diagnosis-specific CD-33 genes were determined with flow cytometry.

[0217]Conjugates of gold nanorods (NR) with and without antibodies to CD33 were used. AML and K562 cells were incubated for 30 min at 37° C. with the gold nanorods with dimensions 45×14 nm and absorption maximum at 780 nm. Then living and fixed cells were used as suspensions for bubble generation and detection.

[0218]Solid tumor cells were prepared as the monolayers of living EGF-positive carcinoma cells (Hep-2C) that we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are methods and systems to increase selective thermomechanical damage to a biological body, such as a cancer cell or cell associated with a pathophysiological condition. The biological body or cancer cell is specifically targeted with nanoparticulates comprising one or more targeting moieties which form nanoparticulate clusters thereon or therewithin. Pulsed electromagnetic radiation, e.g., optical radiation, having a wavelength spectrum selected for a peak wavelength near to or matching a peak absorption wavelength of the nanoparticulates selectively heats the nanoparticulates thereby generating vapor microbubbles around the clusters causing damage to the targets without affecting any surrounding medium or normal cells or tissues. Also provided are methods for treating leukemia and for selectively and thermomechanically causing damage to cells associated with a pathophysiological condition using the methods and system described herein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This is a continuation-in-part application under 35 U.S.C. §120 of pending U.S. Ser. No. 11 / 795,856, filed Jul. 23, 2007, which is a national stage application under 35 U.S.C. 371 of international application PCT / US2006 / 002186, filed Jan. 22, 2006, now abandoned, which claims benefit of priority under 35 U.S.C. 119(e) of provisional U.S. Ser. No. 60 / 646,018, filed Jan. 22, 2005, now abandoned, the entirety of all of which are hereby incorporated by reference.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to the fields of medical therapies employing electromagnetic radiation and of nanoparticles. More specifically, the present invention relates to a method and a system for electromagnetic radiation induced selective destruction of abnormal biological bodies or structures utilizing bioconjugated nanoparticles.[0004]2. Description of the Related Art[0005]In a variety of medical applications, it ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61M1/36C12M1/42C12N13/00B82Y5/00
CPCA61K41/0052A61K47/48653A61K47/48723Y10S977/702A61K47/48884B82Y5/00Y10S977/70A61K47/48861A61K47/6873A61K47/6891A61K47/6923A61K47/6929A61P31/04A61P31/12A61P35/00A61P35/02A61P43/00
Inventor ORAEVSKY, ALEXANDERLAPOTKO, DMITRI
Owner LAPOTKO TATIANA MS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com